{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-23-000035","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.210122+00:00","generated_at":"2026-06-08T12:21:43.133886+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biogen Q3 GAAP loss $0.47/sh, revenue $2.53B; updates FY guidance, highlights LEQEMBI","bullets":["Revenue $2.53B (+1% YoY, +3% CC); GAAP diluted EPS $(0.47); Non-GAAP diluted EPS $4.36 (-9% YoY).","LEQEMBI FDA approval for Alzheimer's, ZURZUVAE for PPD approved; Reata acquisition closed.","Fit for Growth cost savings program of $1B initiated to improve bottom line.","Full-year 2023 guidance updated; new launches expected to drive growth.","Subcutaneous LEQEMBI and tau-directed ASO (BIIB080) show clinical potential."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-23-000035","json":"https://secwatch.observer/filing/0000875045-23-000035.json","markdown":"https://secwatch.observer/filing/0000875045-23-000035.md","text":"https://secwatch.observer/filing/0000875045-23-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504523000035/0000875045-23-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504523000035/biib-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T12:21:43.133886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b8fce5a1279052e4729b63332a262886ef31a38c","claim":"BIOGEN INC. reported third quarter ended September 30, 2023 results: revenue $2,530 million, EPS GAAP diluted EPS $(0.47); Non-GAAP diluted EPS $4.36.","evidence_excerpt":"--- EX-99.1 (EX-99.1) --- Press Release Cambridge, Mass. – Nov. 8, 2023 Biogen reports third quarter 2023 results and updates full year 2023 guidance Third quarter revenue $2,530 million; GAAP diluted EPS $(0.47); Non-GAAP diluted EPS $4.36 Poised for leadership in Alzheimer's disease with ongoing LEQEMBI launch and development of tau-directed ASO (BIIB080) • New","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875045/000087504523000035/0000875045-23-000035-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$2,530 million"},{"label":"EPS","value":"GAAP diluted EPS $(0.47); Non-GAAP diluted EPS $4.36"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}